Your session is about to expire
← Back to Search
Perflutren lipid microsphere for Kidney Cancer
Phase 2
Waitlist Available
Led By Emily Chang, MD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
At least 18 years of age
A suspected diagnosis of kidney cancer with a solid or partially solid lesion and planned surgical nephrectomy within 3 months before surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline- up to 3 minutes
Awards & highlights
Study Summary
This trial will compare the accuracy of contrast-enhanced ultrasound, conventional ultrasound, and MRI in detecting kidney cancer lesions.
Eligible Conditions
- Kidney Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline- up to 3 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline- up to 3 minutes
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. FR_a
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. FR_beta
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Volume
+11 moreSecondary outcome measures
3D CEUS Generated Metric in Kidney Mass - Tumor Stage vs. FR_a
3D CEUS Generated Metric in Kidney Mass - Tumor Stage vs. FR_beta
3D CEUS Generated Metric in Kidney Mass - Tumor Stage vs. Volume
+6 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Perflutren Lipid Microsphere or LumasonExperimental Treatment2 Interventions
Patients with suspected kidney cancer and planned surgery will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perflutren lipid microsphere
2016
Completed Phase 2
~110
Sulfur hexafluoride lipid microspheres
2019
Completed Phase 2
~40
Find a Location
Who is running the clinical trial?
UNC Lineberger Comprehensive Cancer CenterLead Sponsor
348 Previous Clinical Trials
88,219 Total Patients Enrolled
Emily Chang, MDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
1 Previous Clinical Trials
15 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger